Evaluating market performance charts
Markets

Pfizer Catches Two Big Upgrades from Analysts (PFE)

Pharmaceutical giant Pfizer Inc. ( PFE ) on Tuesday saw its shares upgraded by analysts at two major Wall Street firms.

Goldman Sachs added PFE to its prestigious "Conviction Buy" List with a $22 price target, suggesting a 32% upside to the stock's Monday closing price of $16.66. The firm cited the company's solid management team and drug pipeline catalysts in the second half of 2011 for the move.

Meanwhile, Bank of America/Merrill Lynch added PFE to its "US 1″ List, citing the stock's attractive valuation, solid dividend yield, and near-term catalysts. The analyst set a $25 price target on PFE, suggesting an even larger 50% upside.

Pfizer shares rose 24 cents, or +1.4%, in premarket trading Tuesday.

The Bottom Line

We have been recommending shares of Pfizer ( PFE ) since Mar.17, when the stock was trading at $19.30. The company has a 4.80% dividend yield, based on last night's closing stock price of $16.66.

Pfizer Inc. ( PFE ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by Dividend.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PFE

Other Topics

Stocks

Latest Markets Videos